View in EDS

Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.

Saved in:
Bibliographic Details
Title: Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.
Authors: Giménez-Arnau AM; Department of Dermatology, Hospital del Mar and Research Institute, Universitat Pompeu Fabra, Barcelona, Spain. Electronic address: anamariagimenezarnau@gmail.com., Zharkov A; Novartis Pharma AG, Basel, Switzerland., Yang B; Dermatology Hospital of Southern Medical University, Guangdong Provincial Dermatology Hospital, Guangzhou, China., Fukunaga A; Department of Dermatology, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan., Hide M; Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital and Department of Dermatology, Hiroshima University, Hiroshima, Japan., Metz M; Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany., Mosnaim G; Division of Allergy and Immunology, Endeavor Health, Glenview, IL, USA., Staubach P; Department of Dermatology, University Medical Center Mainz, Germany., Gao XH; Department of Dermatology, The First Hospital of China Medical University, Shenyang, China., Jain V; Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada., Burciu A; Novartis Pharma AG, Basel, Switzerland., Cenni B; Novartis Pharma AG, Basel, Switzerland., Haemmerle S; Novartis Pharma AG, Basel, Switzerland., Kuruvilla M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Huang S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Ledieu D; Novartis Pharma AG, Basel, Switzerland., Schuemann J; Novartis Pharma AG, Basel, Switzerland., Scosyrev E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Schneider R; Novartis Pharma AG, Basel, Switzerland., Incera E; IQVIA RDS France, Saint-Ouen-sur-Seine, France., Lheritier K; Novartis Pharma AG, Basel, Switzerland., Tillmann HC; Novartis Pharma AG, Basel, Switzerland., Zouater H; Novartis Pharma AG, Basel, Switzerland., Saini S; Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA.
Source: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2026 Jun 03. Date of Electronic Publication: 2026 Jun 03.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42242425
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Giménez-Arnau+AM%22">Giménez-Arnau AM</searchLink>; Department of Dermatology, Hospital del Mar and Research Institute, Universitat Pompeu Fabra, Barcelona, Spain. Electronic address: anamariagimenezarnau@gmail.com.<br /><searchLink fieldCode="AU" term="%22Zharkov+A%22">Zharkov A</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Yang+B%22">Yang B</searchLink>; Dermatology Hospital of Southern Medical University, Guangdong Provincial Dermatology Hospital, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Fukunaga+A%22">Fukunaga A</searchLink>; Department of Dermatology, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Hide+M%22">Hide M</searchLink>; Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital and Department of Dermatology, Hiroshima University, Hiroshima, Japan.<br /><searchLink fieldCode="AU" term="%22Metz+M%22">Metz M</searchLink>; Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Mosnaim+G%22">Mosnaim G</searchLink>; Division of Allergy and Immunology, Endeavor Health, Glenview, IL, USA.<br /><searchLink fieldCode="AU" term="%22Staubach+P%22">Staubach P</searchLink>; Department of Dermatology, University Medical Center Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Gao+XH%22">Gao XH</searchLink>; Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.<br /><searchLink fieldCode="AU" term="%22Jain+V%22">Jain V</searchLink>; Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Burciu+A%22">Burciu A</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Cenni+B%22">Cenni B</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Haemmerle+S%22">Haemmerle S</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kuruvilla+M%22">Kuruvilla M</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Huang+S%22">Huang S</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Ledieu+D%22">Ledieu D</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schuemann+J%22">Schuemann J</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Scosyrev+E%22">Scosyrev E</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Schneider+R%22">Schneider R</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Incera+E%22">Incera E</searchLink>; IQVIA RDS France, Saint-Ouen-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Lheritier+K%22">Lheritier K</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Tillmann+HC%22">Tillmann HC</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Zouater+H%22">Zouater H</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Saini+S%22">Saini S</searchLink>; Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101597220%22">The journal of allergy and clinical immunology. In practice</searchLink> [J Allergy Clin Immunol Pract] 2026 Jun 03. <i>Date of Electronic Publication: </i>2026 Jun 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101597220 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2213-2201 (Electronic) <i>NLM ISO Abbreviation: </i>J Allergy Clin Immunol Pract <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42242425
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jaip.2026.05.027
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Giménez-Arnau AM
      – PersonEntity:
          Name:
            NameFull: Zharkov A
      – PersonEntity:
          Name:
            NameFull: Yang B
      – PersonEntity:
          Name:
            NameFull: Fukunaga A
      – PersonEntity:
          Name:
            NameFull: Hide M
      – PersonEntity:
          Name:
            NameFull: Metz M
      – PersonEntity:
          Name:
            NameFull: Mosnaim G
      – PersonEntity:
          Name:
            NameFull: Staubach P
      – PersonEntity:
          Name:
            NameFull: Gao XH
      – PersonEntity:
          Name:
            NameFull: Jain V
      – PersonEntity:
          Name:
            NameFull: Burciu A
      – PersonEntity:
          Name:
            NameFull: Cenni B
      – PersonEntity:
          Name:
            NameFull: Haemmerle S
      – PersonEntity:
          Name:
            NameFull: Kuruvilla M
      – PersonEntity:
          Name:
            NameFull: Huang S
      – PersonEntity:
          Name:
            NameFull: Ledieu D
      – PersonEntity:
          Name:
            NameFull: Schuemann J
      – PersonEntity:
          Name:
            NameFull: Scosyrev E
      – PersonEntity:
          Name:
            NameFull: Schneider R
      – PersonEntity:
          Name:
            NameFull: Incera E
      – PersonEntity:
          Name:
            NameFull: Lheritier K
      – PersonEntity:
          Name:
            NameFull: Tillmann HC
      – PersonEntity:
          Name:
            NameFull: Zouater H
      – PersonEntity:
          Name:
            NameFull: Saini S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 06
              Text: 2026 Jun 03
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2213-2201
          Titles:
            – TitleFull: The journal of allergy and clinical immunology. In practice
              Type: main
ResultId 1